208 related articles for article (PubMed ID: 35499386)
1. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
4. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in prostate cancer: time to narrow patient selection?
Markowski MC; Antonarakis ES
Expert Rev Anticancer Ther; 2020 Jul; 20(7):523-526. PubMed ID: 32521178
[No Abstract] [Full Text] [Related]
6. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
[TBL] [Abstract][Full Text] [Related]
8. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors.
Guha M; Sobol Z; Martin M; Hemkens M; Sung T; Rubitski E; Spellman R; Finkelstein M; Khan N; Hu W
Int J Toxicol; 2022 Dec; 41(6):442-454. PubMed ID: 35989659
[TBL] [Abstract][Full Text] [Related]
13. DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
Bryce AH; Sartor O; de Bono J
Eur Urol; 2020 Oct; 78(4):486-488. PubMed ID: 32636098
[TBL] [Abstract][Full Text] [Related]
14. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
15. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
[TBL] [Abstract][Full Text] [Related]
16. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
18. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
19. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]